High MRD levels before transplantation in children receiving T cell-depleted unrelated grafts for relapsed ALL were associated with a 100% relapse risk. We report on two children with relapsed ALL who underwent non T cell-depleted BMT from unrelated donors. Despite a high residual tumor load pretransplant and the occurrence of only aGVHD grade I, they are still in second complete remission 2.7 and 5.2 years after transplantation, respectively. Thus, we propose that the transplant regimens influence the prognostic significance of high MRD levels pre-BMT. Bone Marrow Transplantation (2001) 28, 1087-1089. Keywords: childhood ALL; bone marrow transplantation; minimal residual disease Minimal residual disease analysis by clone-specific IgH and TCR gene rearrangements is accepted as a reliable method for monitoring submicroscopic disease in childhood ALL. Several studies revealed the highly predictive value of MRD in the early phase of front-line chemotherapy.
Minimal residual disease analysis by clone-specific IgH and TCR gene rearrangements is accepted as a reliable method for monitoring submicroscopic disease in childhood ALL. Several studies revealed the highly predictive value of MRD in the early phase of front-line chemotherapy. [1] [2] [3] Recent emphasis is being placed on the application of MRD before transplantation, since one of the major problems after SCT is the high incidence of relapses even in patients transplanted in morphological remission. Thus, the detection of submicroscopic levels of leukemic cell burden is thought to be of additional prognostic value in outcome prediction after allo-BMT for ALL.
Recently, Knechtli et al 4 showed that high MRD levels of equal or more than 10 −3 within 4 weeks before transplantation were significantly correlated with a poor outcome after transplantation. Their study was performed in children with ALL transplanted from T cell-depleted matched and mismatched unrelated grafts in first, second or subsequent remission. We report here on two children who underwent allogeneic BMT for relapsed ALL with non-T cell-depleted grafts from unrelated donors. Both chil- dren had high MRD levels of equal or more than 10 −2 using clonotypic IgH and TCR gene rearrangements as molecular markers 3 weeks before transplantation. They are still in CR after an observation time of 2.7 and 5.2 years from transplantation, respectively. These data suggest that different transplantation regimens may influence outcome after BMT in childhood ALL and, thus, the prognostic value of MRD analysis pre-BMT.
Patients
We retrospectively analyzed MRD levels 2 to 4 weeks before allogeneic non-T cell-depleted BMT in 13 children with ALL. Two of the four patients with high MRD levels of equal or more than 10 −2 pre-BMT did not relapse and are reported here. Both children were treated according to current BFM protocols (ALL-BFM 90; ALL-Rez-BFM 96 protocol). 5 They were in morphological remission before BMT. Bone marrow graft processing and supportive care were done according to standard procedures. HLA compatibility was assessed by conventional serological typing for class I and class II, and by DNA sequencing of class II antigens.
Patient 1
Pre-B ALL was diagnosed in a female aged 11.3 years. WBC count at diagnosis was 68 × 10 9 /l. Cytogenetic analysis revealed a normal karyotype. The absence of a t(9;22) or t(4;11) was confirmed by PCR. The patient was treated according to the BFM high-risk protocol because of a poor prednisone response. An isolated relapse in the bone marrow occurred 18 months after completion of first-line chemotherapy. After 3 weeks of intensive chemotherapy, a second complete remission was achieved. Consolidation treatment followed and 10 months later the patient underwent allogeneic bone marrow transplantation.
Twenty-four days before transplantation, MRD analysis showed a tumour load of 10 
Patient 2
Common ALL was diagnosed in a male at the age of 4.4 years. WBC count at diagnosis was 2 × 10 9 /l. Cytogenetic analysis revealed a hyperdiploid clone. He received frontline treatment according to the BFM protocol, but no remission was achieved after induction therapy (day 33). Remission was documented after the first high-risk course. Six months later the patient suffered from a relapse in the bone marrow while still on high-risk block therapy. Intensive remission induction treatment followed and 2 weeks later a second morphological remission was achieved. Three weeks later he was transferred for bone marrow transplantation. MRD analysis 19 days before transplantation revealed a level of 10 −2 . The patient received unmanipulated marrow (1.7 × 10 6 /kg CD34 + cells and 1 × 10 7 /kg CD3 + cells) from an unrelated donor. HLA typing revealed compatibility at HLA-A, -B, -Cw, -DR and -DQB1, and a minor mismatch at -DPB1. The conditioning regimen consisted of TBI eight doses of 1.5 Gy on 4 consecutive days (total dose 12 Gy), cyclophosphamide 60 mg/kg i.v. on day 3 and 2 (total dose 120 mg/kg) and rabbit ATG Sero Merieux 15 mg/kg i.v. from days −12 to −8 (total dose 75 mg/kg). For GVHD prophylaxis CsA 3 mg/kg p.o. and MTX 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3 and 6 was administered. Signs of aGVHD grade I of the skin resolved after an additional application of prednisone 4 mg/kg p.o. on 7 consecutive days, followed by 2 mg/kg p.o. for 2 weeks. No symptoms of chronic GVHD developed. The patient is still in second CR 5.2 years after BMT.
Methods
Bone marrow samples were analyzed at initial diagnosis of ALL, relapse and before BMT in both patients. DNA preparation and identification of clone-specific antigen receptor gene rearrangements by polymerase chain reaction (PCR) techniques were done according to standardized protocols as described previously. 6 Junctional region-specific oligonucleotides were used for dot blot hybridization of amplified DNA from bone marrow MNC at relapse and before SCT. The amount of residual leukemia was estimated by comparing the signal of the follow-up sample with a log dilution of leukemic cells from relapse into DNA from peripheral blood MNC from healthy donors. A sensitivity of 10 −4 or more was achieved in all analyses.
Discussion
We report here on two children with high MRD loads of equal or more than 10 −2 3 weeks before allogeneic BMT for relapsed ALL. Both children received bone marrow from unrelated donors. In one patient the graft was fully HLAmatched, in the other the graft had one minor mismatch. The patients developed aGVHD grade I of the skin and are now in second CR for 2.7 and 5.2 years after BMT, respectively.
In a recent publication Knechtli and colleagues 4 reported on the prognostic impact of MRD before allogeneic BMT in childhood ALL in a retrospective study of 56 children receiving T cell-depleted BMT. High-level MRD of equal or more than 10 −3 was detected in 12 children 1 to 11 weeks before transplantation with a 2-year event-free survival of 0%. In contrast to the study of Knechtli et al, we did not observe relapses in two children with high-level MRD before transplantation. The main difference between the studies from Knechtli et al and our own was the conditioning regimen and graft manipulation. Their patients received in vitro T cell-depleted grafts from unrelated donors using Campath-1M or -1G, and in addition, intravenous application of Campath-1G. Our patients received unmanipulated bone marrow from unrelated donors. No Campath was administered. The patients in this report received ATG on days −12 to −8 (patient 2) and on days −3 to −1 (patient 1), respectively, before BMT. In the latter patient immunosuppressive levels of ATG on the transfused graft are expected. 7 We propose that non-T cell-depleted grafts and thus a better graft-versus-leukemia effect might have influenced the successful elimination of residual leukemia in our two patients with high-level MRD before transplantation. This assumption is supported by previous studies reporting a higher incidence of leukemia relapse using Campath-1G in the conditioning regimen and T cell-depleted grafts. 8, 9 Our data on the favorable outcome of two patients with high-level MRD before transplantation with unmanipulated grafts are supported by a recent report from Uzunel et al, 10 who show that less than 50% of patients transplanted with unmanipulated grafts do not relapse despite the presence of residual disease before BMT. Furthermore their study demonstrates a strong correlation between the occurrence of acute and chronic GVHD and sustained remission.
We would like to conclude that graft manipulation and/or conditioning regimen have an impact on the outcome of patients transplanted with high MRD loads. Prospective studies are needed to evaluate the prognostic power of MRD before stem cell transplantation under different conditioning regimens.
